

Daniel E Weiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594792/publications.pdf>

Version: 2024-02-01

232
papers

15,613
citations

22099

59
h-index

19690

117
g-index

239
all docs

239
docs citations

239
times ranked

17853
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1307-1315.	3.0	1,072
2	KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. <i>American Journal of Kidney Diseases</i> , 2015, 66, 884-930.	2.1	822
3	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 553.	3.8	786
4	Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. <i>JAMA Internal Medicine</i> , 2020, 180, 1436.	2.6	711
5	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	2.6	407
6	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
7	Uric Acid and Incident Kidney Disease in the Community. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1204-1211.	3.0	387
8	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	2.1	362
9	The Framingham Predictive Instrument in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 217-224.	1.2	285
10	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 524.	3.8	285
11	Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3403-3410.	3.0	272
12	Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction Between CKD and Cardiovascular Disease. <i>American Journal of Kidney Diseases</i> , 2006, 48, 392-401.	2.1	265
13	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD). <i>American Journal of Kidney Diseases</i> , 2017, 70, 737-751.	2.1	257
14	Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. <i>American Journal of Kidney Diseases</i> , 2004, 44, 198-206.	2.1	243
15	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	2.6	235
16	Waist-to-Hip Ratio, Body Mass Index, and Subsequent Kidney Disease and Death. <i>American Journal of Kidney Diseases</i> , 2008, 52, 29-38.	2.1	224
17	Chronic Kidney Disease and End-Stage Renal Disease in the Elderly Population: Current Prevalence, Future Projections, and Clinical Significance. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 293-301.	0.6	204
18	Cardiovascular Disease and Subsequent Kidney Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 1130.	4.3	201

#	ARTICLE	IF	CITATIONS
19	Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. <i>American Journal of Kidney Diseases</i> , 2019, 74, 782-790.	2.1	188
20	Chronic Kidney Disease Associated With Environmental Toxins and Exposures. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 254-264.	0.6	186
21	Frequency of and risk factors for poor cognitive performance in hemodialysis patients. <i>Neurology</i> , 2013, 80, 471-480.	1.5	186
22	COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. <i>American Journal of Kidney Diseases</i> , 2021, 77, 748-756.e1.	2.1	181
23	Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1803-1810.	3.0	180
24	Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. <i>New England Journal of Medicine</i> , 2017, 377, 733-744.	13.9	160
25	Critical and Honest Conversations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1664-1672.	2.2	157
26	Cognitive function in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 448-462.	2.1	154
27	The Challenges of the Next 5 Years. <i>American Journal of Kidney Diseases</i> , 2007, 49, 1-2.	2.1	151
28	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology "Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	2.1	148
29	Albuminuria, Cognitive Functioning, and White Matter Hyperintensities in Homebound Elders. <i>American Journal of Kidney Diseases</i> , 2009, 53, 438-447.	2.1	141
30	Staying Put, But Not Standing Still. <i>American Journal of Kidney Diseases</i> , 2012, 59, 1-3.	2.1	136
31	Waist-to-Hip Ratio and Body Mass Index as Risk Factors for Cardiovascular Events in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 52, 49-57.	2.1	133
32	The Relationship Between Nontraditional Risk Factors and Outcomes in Individuals With Stage 3 to 4 CKD. <i>American Journal of Kidney Diseases</i> , 2008, 51, 212-223.	2.1	131
33	Improving Clinical Outcomes Among Hemodialysis Patients: A Proposal for a "Volume First" Approach From the Chief Medical Officers of US Dialysis Providers. <i>American Journal of Kidney Diseases</i> , 2014, 64, 685-695.	2.1	131
34	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 861-876.	2.6	126
35	Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2017, 69, 266-277.	2.1	123
36	A Palliative Approach to Dialysis Care. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 2203-2209.	2.2	120

#	ARTICLE	IF	CITATIONS
37	Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2798-2805.	0.4	114
38	Depression and Cognitive Function in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 704-712.	2.1	112
39	Vascular Access Choice in Incident Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 183-191.	3.0	110
40	Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial. <i>American Journal of Transplantation</i> , 2012, 12, 2437-2445.	2.6	103
41	Anatomic Brain Disease in Hemodialysis Patients: A Cross-sectional Study. <i>American Journal of Kidney Diseases</i> , 2013, 61, 271-278.	2.1	103
42	Changes in kidney function among Nicaraguan sugarcane workers. <i>International Journal of Occupational and Environmental Health</i> , 2015, 21, 241-250.	1.2	103
43	Biomarkers of Kidney Injury Among Nicaraguan Sugarcane Workers. <i>American Journal of Kidney Diseases</i> , 2016, 67, 209-217.	2.1	97
44	Cardiovascular Disease and Cognitive Function in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2011, 58, 773-781.	2.1	95
45	Cognitive Function and All-Cause Mortality in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2015, 65, 303-311.	2.1	95
46	Lowest Systolic Blood Pressure Is Associated with Stroke in Stages 3 to 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 960-966.	3.0	93
47	The Central American Epidemic of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 504-511.	2.2	91
48	Discussing Conservative Management With Older Patients With CKD: An Interview Study of Nephrologists. <i>American Journal of Kidney Diseases</i> , 2018, 71, 627-635.	2.1	87
49	Oral Intradialytic Nutritional Supplement Use and Mortality in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2014, 63, 276-285.	2.1	85
50	Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1887-1896.	0.5	83
51	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
52	Subcortical cognitive impairment in dialysis patients. <i>Hemodialysis International</i> , 2007, 11, 309-314.	0.4	78
53	Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 69, 780-787.	2.1	76
54	Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. <i>Seminars in Nephrology</i> , 2015, 35, 311-322.	0.6	71

#	ARTICLE	IF	CITATIONS
55	Managing dyslipidemia in chronic kidney disease. <i>Journal of General Internal Medicine</i> , 2004, 19, 1045-1052.	1.3	70
56	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
57	Public Health Consequences of Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 566-569.	2.3	67
58	“End-of-Life Care? I’m not Going to Worry About That Yet.” Health Literacy Gaps and End-of-Life Planning Among Elderly Dialysis Patients. <i>Gerontologist</i> , The, 2018, 58, 290-299.	2.3	65
59	Perceptions of Telehealth vs In-Person Visits Among Older Adults With Advanced Kidney Disease, Care Partners, and Clinicians. <i>JAMA Network Open</i> , 2021, 4, e2137193.	2.8	65
60	Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2735-2742.	3.0	64
61	Acute Kidney Injury in Sugarcane Workers at Risk for Mesoamerican Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018, 72, 475-482.	2.1	62
62	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1554-1562.	3.0	60
63	Engagement in decision-making and patient satisfaction: a qualitative study of older patients' perceptions of dialysis initiation and modality decisions. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw307.	0.4	60
64	Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 357-367.	2.1	60
65	Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1801-1810.	3.0	56
66	Urine biomarkers of kidney injury among adolescents in Nicaragua, a region affected by an epidemic of chronic kidney disease of unknown aetiology. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 424-432.	0.4	56
67	Depression and All-Cause Mortality in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2014, 40, 12-18.	1.4	54
68	Chronic kidney disease in Nicaragua: a qualitative analysis of semi-structured interviews with physicians and pharmacists. <i>BMC Public Health</i> , 2013, 13, 350.	1.2	53
69	Cognitive impairment in chronic kidney disease: keep vascular disease in mind. <i>Kidney International</i> , 2014, 85, 505-507.	2.6	53
70	Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1310-1319.	2.2	50
71	The ESRD Quality Incentive Program—Can We Bridge the Chasm?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1697-1706.	3.0	49
72	Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2017, 69, 410-419.	2.1	49

#	ARTICLE	IF	CITATIONS
73	Cognitive and physical function in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 291-297.	1.0	48
74	Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. <i>Neurology</i> , 2016, 86, 1208-1216.	1.5	48
75	Characterization of Mesoamerican Nephropathy in a Kidney Failure Hotspot in Nicaragua. <i>American Journal of Kidney Diseases</i> , 2016, 68, 716-725.	2.1	47
76	Characterizing Approaches to Dialysis Decision Making with Older Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1188-1196.	2.2	47
77	Causes and Consequences of Chronic Kidney Disease: Implications for Managed Health Care. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 1-9.	2.2	46
78	Hematocrit and left ventricular mass: the Framingham Heart study. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1276-1282.	1.2	45
79	Cognitive Function and Dialysis Adequacy: No Clear Relationship. <i>American Journal of Nephrology</i> , 2011, 33, 33-38.	1.4	45
80	The Kidney Disease Quality of Life Cognitive Function Subscale and Cognitive Performance in Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2012, 60, 417-426.	2.1	45
81	Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure—This study was presented in abstract form at the American Society of Nephrology meetings in 2005.. <i>American Journal of Cardiology</i> , 2007, 99, 1137-1142.	0.7	43
82	Circulating Vitamin K Is Inversely Associated with Incident Cardiovascular Disease Risk among Those Treated for Hypertension in the Health, Aging, and Body Composition Study (Health ABC). <i>Journal of Nutrition</i> , 2017, 147, 888-895.	1.3	43
83	Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 403-413.	2.2	43
84	Kidney Disease, Framingham Risk Scores, and Cardiac and Mortality Outcomes. <i>American Journal of Medicine</i> , 2007, 120, 552.e1-552.e8.	0.6	42
85	Inflammation and cardiovascular events in individuals with and without chronic kidney disease. <i>Kidney International</i> , 2008, 73, 1406-1412.	2.6	42
86	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 479-488.	2.1	41
87	Evaluation of Screening Tests for Cognitive Impairment in Patients Receiving Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 855-864.	3.0	41
88	Transvenous Cardiac Device Wires and Vascular Access in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2011, 58, 494-496.	2.1	40
89	Kidney function, albuminuria and age-related macular degeneration in NHANES III. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3159-3165.	0.4	40
90	Nephrologist-Facilitated Advance Care Planning for Hemodialysis Patients: A Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2016, 68, 103-109.	2.1	40

#	ARTICLE	IF	CITATIONS
91	<i>Leptospira</i> seropositivity as a risk factor for Mesoamerican Nephropathy. International Journal of Occupational and Environmental Health, 2017, 23, 1-10.	1.2	39
92	Changes in Anthropometry and Mortality in Maintenance Hemodialysis Patients in the HEMO Study. American Journal of Kidney Diseases, 2013, 62, 1141-1150.	2.1	38
93	<scp>FGF</scp> ≥ 23 and cognitive performance in hemodialysis patients. Hemodialysis International, 2014, 18, 78-86.	0.4	37
94	Hemodialysis and COVID-19: An Achillesâ€™ Heel in the Pandemic Health Care Response in the United States. Kidney Medicine, 2020, 2, 227-230.	1.0	37
95	White matter damage in maintenance hemodialysis patients: a diffusion tensor imaging study. BMC Nephrology, 2017, 18, 213.	0.8	36
96	COVID-19 in dialysis patients: outlasting and outsmarting a pandemic. Kidney International, 2020, 98, 1402-1404.	2.6	36
97	Computerized Decision Support for EPO Dosing in Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 54, 1081-1088.	2.1	35
98	Left Ventricular Assist Devices, Kidney Disease, and Dialysis. American Journal of Kidney Diseases, 2018, 71, 257-266.	2.1	35
99	Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. American Journal of Kidney Diseases, 2019, 74, 620-628.	2.1	34
100	CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrology, 2009, 10, 26.	0.8	32
101	Uric Acid, CKD, and Cardiovascular Disease: Confounders, Culprits, and Circles. American Journal of Kidney Diseases, 2010, 56, 247-250.	2.1	32
102	A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease. Pharmacoeconomics, 2011, 29, 839-861.	1.7	32
103	Medicare Reimbursement Policies and Hemodialysis Vascular Access Outcomes: A Need for Change: Table 1.. Journal of the American Society of Nephrology: JASN, 2011, 22, 426-430.	3.0	31
104	Comparing Mandated Health Care Reforms. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1535-1543.	2.2	31
105	Cognitive Impairment in Dialysis Patients: Focus on the Blood Vessels?. American Journal of Kidney Diseases, 2013, 61, 187-190.	2.1	31
106	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American Journal of Nephrology, 2018, 47, 275-282.	1.4	31
107	Medicare Advantage Ratings And Voluntary Disenrollment Among Patients With End-Stage Renal Disease. Health Affairs, 2018, 37, 70-77.	2.5	31
108	Cognitive Dysfunction and Depression in Adult Kidney Transplant Recipients: Baseline Findings from the FAVORIT Ancillary Cognitive Trial (FACT). , 2012, 22, 268-276.e3.		30

#	ARTICLE	IF	CITATIONS
109	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2019, 73, 51-61.	2.1	30
110	Advance Care Planning in Older Adults with CKD: Patient, Care Partner, and Clinician Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1527-1535.	3.0	30
111	Low 25-Hydroxyvitamin D Levels and Cognitive Impairment in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 979-986.	2.2	29
112	Peripherally Inserted Central Catheters and Hemodialysis Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1434-1440.	2.2	29
113	Telehealth and Home Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1288-1290.	2.2	29
114	What can we learn from the U.S. expanded end-stage renal disease bundle?. <i>Health Policy</i> , 2013, 110, 164-171.	1.4	28
115	Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 602-614.	3.0	28
116	Ultrafiltration Rate Thresholds in Maintenance Hemodialysis: An NKF-KDOQI Controversies Report. <i>American Journal of Kidney Diseases</i> , 2016, 68, 522-532.	2.1	27
117	Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2016, 67, 439-445.	2.1	27
118	Cognitive Performance before and during Hemodialysis: A Randomized Cross-Over Trial. <i>Nephron Clinical Practice</i> , 2014, 124, 151-158.	2.3	26
119	Home Dialysis in the United States: A Roadmap for Increasing Peritoneal Dialysis Utilization. <i>American Journal of Kidney Diseases</i> , 2020, 75, 413-416.	2.1	26
120	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. <i>JAMA Neurology</i> , 2022, 79, 380.	4.5	26
121	Reduced speed of microvascular blood flow in hemodialysis patients versus healthy controls: a coherent hemodynamics spectroscopy study. <i>Journal of Biomedical Optics</i> , 2014, 19, 026005.	1.4	25
122	Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2122-2132.	3.0	25
123	Epidemiology and Outcomes of COVID-19 in Home Dialysis Patients Compared with In-Center Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1569-1573.	3.0	25
124	Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2109-2121.	3.0	24
125	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	2.1	24
126	Dialysate Composition for Hemodialysis: Changes and Changing Risk. <i>Seminars in Dialysis</i> , 2017, 30, 112-120.	0.7	23

#	ARTICLE	IF	CITATIONS
127	Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. <i>American Journal of Kidney Diseases</i> , 2017, 70, 377-385.	2.1	23
128	Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 1170-1177.	2.2	23
129	Kidney Recovery and Death in Critically Ill Patients With COVID-19â€™Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 404-416.e1.	2.1	23
130	Multidisciplinary Medication Therapy Management and Hospital Readmission in Patients Undergoing Maintenance Dialysis: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 13-21.	2.1	22
131	Association of sleep disturbances with cognitive impairment and depression in maintenance hemodialysis patients. <i>Journal of Nephrology</i> , 2013, 26, 101-110.	0.9	22
132	Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2022, 79, 307-310.	2.1	22
133	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	0.8	20
134	Health Policy and Kidney Care in the United States: Core Curriculum 2020. <i>American Journal of Kidney Diseases</i> , 2020, 76, 720-730.	2.1	20
135	Heart failure management in dialysis patients: Many treatment options with no clear evidence. <i>Seminars in Dialysis</i> , 2020, 33, 198-208.	0.7	20
136	Value-Based Care in Nephrology: The Kidney Care Choices Model and Other Reforms. <i>Kidney360</i> , 2021, 2, 1677-1683.	0.9	20
137	The Cognitionâ€™Kidney Disease Connection: Lessons From Population-Based Studies in the United States. <i>American Journal of Kidney Diseases</i> , 2008, 52, 201-204.	2.1	19
138	Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 277-286.	2.1	19
139	Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain. <i>Seminars in Dialysis</i> , 2017, 30, 203-212.	0.7	19
140	Patient Education for Kidney Failure Treatment: A Mixed-Methods Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 690-699.	2.1	19
141	Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 3184-3191.	3.0	16
142	Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1377-1384.	0.4	16
143	A Decade After the KDOQI CKD Guidelines: Impact on the Cardiovascular Diseaseâ€™CKD Paradigm. <i>American Journal of Kidney Diseases</i> , 2012, 60, 710-712.	2.1	15
144	Asymmetric Dimethylarginine, Race, and Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1426-1433.	2.2	15

#	ARTICLE	IF	CITATIONS
145	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1121-1128.	2.2	15
146	Advance Care Planning Among Older Adults With Advanced Non-Dialysis-Dependent CKD and Their Care Partners: Perceptions Versus Reality?. <i>Kidney Medicine</i> , 2020, 2, 116-124.	1.0	15
147	Shared Decision Making Among Older Adults With Advanced CKD. <i>American Journal of Kidney Diseases</i> , 2022, 80, 599-609.	2.1	15
148	In Reply to "Etiological Versus Prognostic Models in Cohort Studies" and "Nutritional Supplement Use in Hemodialysis Patients". <i>American Journal of Kidney Diseases</i> , 2014, 63, 1068.	2.1	14
149	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	1.1	14
150	Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT. <i>American Journal of Kidney Diseases</i> , 2021, 78, 530-540.e1.	2.1	13
151	The 2009 Proposed Rule for Prospective ESRD Payment: Historical Perspectives and Public Policies "Bundle Up!". <i>American Journal of Kidney Diseases</i> , 2010, 55, 217-222.	2.1	12
152	Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). <i>Kidney360</i> , 2021, 2, 1600-1610.	0.9	12
153	Timing Hemodialysis Initiation: A Call for Clinical Judgment. <i>American Journal of Kidney Diseases</i> , 2011, 57, 562-565.	2.1	11
154	Oral nutritional supplements and 30-day readmission rate in hypoalbuminemic maintenance hemodialysis patients. <i>Hemodialysis International</i> , 2019, 23, 93-100.	0.4	11
155	Microalbuminuria: a marker of cardiovascular risk. <i>American Journal of Kidney Diseases</i> , 2003, 42, 596-598.	2.1	10
156	B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 182-190.	0.5	10
157	Blood Pressure and Cognitive Decline in Prevalent Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2019, 49, 460-469.	1.4	10
158	The 2011 ESRD Prospective Payment System: Welcome to the Bundle. <i>American Journal of Kidney Diseases</i> , 2011, 57, 539-541.	2.1	9
159	Exercise to Improve Physical Function and Quality of Life in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 2023-2024.	2.2	9
160	Allopurinol as a Kidney-Protective, Cardioprotective, and Antihypertensive Agent: Hype or Reality?. <i>Blood Purification</i> , 2014, 37, 172-178.	0.9	9
161	Better Informing Older Patients With Kidney Failure in an Era of Patient-Centered Care. <i>American Journal of Kidney Diseases</i> , 2015, 65, 372-374.	2.1	9
162	Hemodialysis patient characteristics associated with better experience as measured by the In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey. <i>BMC Nephrology</i> , 2018, 19, 340.	0.8	9

#	ARTICLE	IF	CITATIONS
163	Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 941-948.	2.2	9
164	Treatment Decision Making for Older Kidney Patients during COVID-19. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 957-965.	2.2	9
165	Anemia Management in Chronic Kidney Disease: Bursting the Hemoglobin Bubble. <i>Annals of Internal Medicine</i> , 2010, 153, 53.	2.0	8
166	Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial. <i>American Journal of Hypertension</i> , 2019, 32, 816-823.	1.0	8
167	COVID-19 Infection Risk Among Hemodialysis Patients in Long-term Care Facilities. <i>Kidney Medicine</i> , 2020, 2, 810-811.	1.0	8
168	Nephrologist Performance in the Merit-Based Incentive Payment System. <i>Kidney Medicine</i> , 2021, 3, 816-826.e1.	1.0	8
169	The ESRD Quality Incentive Program: Everything Can Be Improved. <i>American Journal of Kidney Diseases</i> , 2021, 78, 907-910.	2.1	8
170	Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis. <i>American Journal of Kidney Diseases</i> , 2022, 80, 151-153.	2.1	8
171	Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. <i>American Journal of Kidney Diseases</i> , 2012, 59, 170-173.	2.1	7
172	Measures of blood pressure and cognition in dialysis patients. <i>Hemodialysis International</i> , 2013, 17, 24-31.	0.4	7
173	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle": Iron(y) Abounds 2 Years Later. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1217-1220.	2.1	7
174	In Reply to "More Evidence Needed Before Lower Dialysate Sodium Concentrations Can Be Recommended". <i>American Journal of Kidney Diseases</i> , 2015, 65, 520.	2.1	7
175	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through August 2011": An ESA Confluence. <i>American Journal of Kidney Diseases</i> , 2012, 60, 165-167.	2.1	6
176	Estimation of Life-Years Saved by Solid-Organ Transplant. <i>JAMA Surgery</i> , 2015, 150, 1015.	2.2	6
177	Nutrition, vitamin D, and health outcomes in hemodialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 546-556.	1.0	6
178	Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1603-1613.	2.2	6
179	Home Dialysis in the United States: To Increase Utilization, Address Disparities. <i>Kidney Medicine</i> , 2020, 2, 95-97.	1.0	6
180	Dialysis and Total Health Care Costs in the United States and Worldwide: The Financial Impact of a Single-Payer Dominant System in the US. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2137-2139.	3.0	6

#	ARTICLE	IF	CITATIONS
181	Mobility in Older Adults Receiving Maintenance Hemodialysis: A Qualitative Study. American Journal of Kidney Diseases, 2022, 79, 539-548.e1.	2.1	6
182	Fluid First or Not So Fast: Ultrafiltration Rate and the ESRD Quality Incentive Program. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1330-1332.	2.2	5
183	Risk of renal cell carcinoma following exposure to metalworking fluids among autoworkers. Occupational and Environmental Medicine, 2016, 73, 656-662.	1.3	5
184	Peripherally Inserted Central Catheters (PICCs) in CKD: PICCâ€™ing the Best Access for Kidney Disease Patients. American Journal of Kidney Diseases, 2016, 67, 724-727.	2.1	5
185	High-Dose Versus Standard-Dose Influenza Vaccine in Hemodialysis Patients. American Journal of Kidney Diseases, 2020, 75, 456.	2.1	5
186	Epidemiology of End-Stage Renal Disease. , 2016, , 3-13.		5
187	Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2022, 80, 309-318.	2.1	5
188	Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases. Kidney Medicine, 2022, 4, 100442.	1.0	5
189	Oral Nutritional Supplement Use in Dialysis Patients: Full Speed Ahead?. American Journal of Kidney Diseases, 2012, 60, 507-509.	2.1	4
190	Vascular imaging for hemodialysis vascular access planning. Hemodialysis International, 2017, 21, 490-497.	0.4	4
191	Assessing quality care in kidney disease: The doubleâ€™edged sword versus the Gordian knot. Seminars in Dialysis, 2020, 33, 10-17.	0.7	4
192	Long-term Clinical Outcomes Among Responders and Nonresponders to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) Survey. Kidney Medicine, 2020, 2, 181-188.	1.0	4
193	Dysuria, heat stress, and muscle injury among Nicaraguan sugarcane workers at risk for Mesoamerican nephropathy. Scandinavian Journal of Work, Environment and Health, 2021, 47, 377-386.	1.7	4
194	Kidney Function, Self-Reported Symptoms, and Urine Findings in Nicaraguan Sugarcane Workers. Kidney360, 2020, 1, 1042-1051.	0.9	4
195	Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. Hemodialysis International, 2022, 26, 449-455.	0.4	4
196	Vitamin K Status and Cognitive Function in Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. Current Developments in Nutrition, 2022, 6, nza111.	0.1	4
197	Chronic kidney disease and cardiovascular disease: A bi-directional relationship?. Dialysis and Transplantation, 2007, 36, 113-120.	0.2	3
198	In the Literature: Cognitive Impairment in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 183-185.	2.1	3

#	ARTICLE	IF	CITATIONS
199	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An Overview. American Journal of Kidney Diseases, 2007, 50, 349-353.	2.1	3
200	Kidney function and the risk of cardiovascular disease. BMJ: British Medical Journal, 2009, 338, b1307-b1307.	2.4	3
201	Risk Factors for ESRD: Lessons From a Community Study and Implications for Public Health. American Journal of Kidney Diseases, 2010, 55, 5-7.	2.1	3
202	Nadir Hemoglobin Levels after Discontinuation of Epoetin in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1621-1627.	2.2	3
203	The Affordable Care Act, Kidney Transplant Access, and Kidney Disease Care in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 982-983.	2.2	3
204	Value-Based Kidney Care: Aligning Metrics and Incentives to Improve the Health of People with Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 2282-2284.	3.0	3
205	End-stage renal disease and metalworking fluid exposure. Occupational and Environmental Medicine, 2022, 79, 24-31.	1.3	3
206	Ten Years Atop the Masthead. American Journal of Kidney Diseases, 2016, 68, 825-827.	2.1	2
207	Does an Aspirin a Day Keep the Doctor Away?. American Journal of Kidney Diseases, 2017, 69, 337-340.	2.1	2
208	Readmissions Metrics in Hemodialysis: Do the Specifics Matter?. Journal of the American Society of Nephrology: JASN, 2019, 30, 184-186.	3.0	2
209	Value-Based Care in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 14-16.	2.2	2
210	Utilizing the Probation Office as an Opportunity to Screen for Cardiometabolic Outcomes: A Feasibility Study. Journal of Correctional Health Care, 2022, 28, 274-282.	0.2	2
211	A New Forum for Brief Research Reports in AJKD. American Journal of Kidney Diseases, 2010, 55, 975-976.	2.1	1
212	Cardiovascular Disease in Patients with Chronic Kidney Disease. , 2010, , 128-144.		1
213	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through April 2011": No Surprises Yet. American Journal of Kidney Diseases, 2012, 59, 312-314.	2.1	1
214	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through December 2011": Results From Year One. American Journal of Kidney Diseases, 2013, 61, 346-348.	2.1	1
215	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2014, , 488-496.		1
216	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder Among US Hemodialysis Patients": The Calm Before the 2016 Storm?. American Journal of Kidney Diseases, 2014, 63, 854-858.	2.1	1

#	ARTICLE	IF	CITATIONS
217	Kidney Transplantation in Lupus Nephritis: Can We Do Even Better?. Annals of Internal Medicine, 2019, 170, 266.	2.0	1
218	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2020, 31, 2966-2966.	3.0	1
219	COVID-19 Universal Testing in Hemodialysis Facilities to Reduce Infection Risk. Kidney Medicine, 2020, 2, 681-683.	1.0	1
220	The Relationship of Kidney Tubule Biomarkers with Brain Imaging in CKD Patients in SPRINT. Kidney360, 2022, 3, 337-340.	0.9	1
221	A 50-Year-Old Man with Chest Pain. American Journal of the Medical Sciences, 2003, 325, 70-74.	0.4	0
222	Cardiovascular Disease in Patients with Chronic Kidney Disease. , 2005, , 158-173.		0
223	Kidney Disease and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2013, 310, 697.	3.8	0
224	Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. , 2013, , 123-135.		0
225	[P2â€™013]: Bâ€™VITAMIN THERAPY LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL. Alzheimer's and Dementia, 2017, 13, P609.	0.4	0
226	Kidney Medicine: Whatâ€™s in a Name?. Kidney Medicine, 2019, 1, 1-2.	1.0	0
227	Cardiovascular Disease in Chronic Kidney Disease. , 2019, , 176-193.e9.		0
228	Effect of intensive versus standard blood pressure control on cerebral blood flow in SPRINT. Alzheimer's and Dementia, 2020, 16, e042155.	0.4	0
229	GFR decline and prior dysuria among Nicaraguan sugarcane workers. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
230	AJKD at 40: The Boston Eraâ€™Years 25-35 (2007-2016). American Journal of Kidney Diseases, 2021, 78, 475-476.	2.1	0
231	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2009, , 499-505.		0
232	Prevention and management of cardiovascular disease in kidney disease and kidney failure. , 2022, , 207-223.		0